Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 3/20 | 0.37 |
| ▸ | CCNC | P24863 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 5/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 4/20 | 0.35 |
| ▸ | GSK3B | P49841 | 4/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.35 |
| ▸ | KRAS | P01116 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31677759 | 0.91 | FLT3 (0.42) | FLT3WNT3ACCNCCDK8HTR2A | |
| SCHEMBL29619165 | 0.88 | FLT3 (0.41) | FLT3WNT3AHTR2AHTR2CCREBBP | |
| SCHEMBL29619114 | 0.86 | WNT3A (0.44) | FLT3WNT3AHTR2AHTR2CCREBBP | |
| SCHEMBL29619066 | 0.85 | HTR2A (0.40) | FLT3WNT3AHTR2AHTR2CCREBBP | |
| SCHEMBL29619067 | 0.85 | HTR2A (0.40) | FLT3WNT3AHTR2AHTR2CCREBBP | |
| SCHEMBL29619043 | 0.81 | HTR2A (0.50) | HTR2AHTR2C | |
| SCHEMBL29619052 | 0.81 | HTR2A (0.48) | HTR2AHTR2C | |
| SCHEMBL29619057 | 0.81 | MET (0.44) | METAXLHTR2ACREBBP | |
| SCHEMBL29619001 | 0.80 | ESR1 (0.35) | FLT3KRAS | |
| SCHEMBL29619005 | 0.80 | ESR1 (0.35) | FLT3KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4236942-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022093850-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | HTR2A, HTR5A, HTR1A | FLT3 4847/4885MET 4151/4885AXL 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.